• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.

作者信息

Ryan J R, Chremos A N, Vargas R, Mantell G, Johnson C L, McMahon F G

出版信息

Clin Pharmacol Ther. 1987 Aug;42(2):225-31. doi: 10.1038/clpt.1987.136.

DOI:10.1038/clpt.1987.136
PMID:2886245
Abstract

The antisecretory profile of the H2-receptor antagonist famotidine was studied with various oral doses and regimens in 10 healthy volunteers with high basal acid output (greater than or equal to 5 mEq/hr). Doses included 10, 20, and 40 mg at 9 PM and 9 AM and also 40 mg at 9 PM only. In the 22 hours after the PM doses, overnight (midnight to 7 AM) basal acid secretion was evaluated. Daytime meal-stimulated secretion was assessed at 7 AM, 12 noon, and 5 PM. Doses of 10, 20, and 40 mg inhibited fasting nocturnal basal secretion by 69%, 86%, and 83% to 94%, respectively (P less than 0.01). Meal-stimulated secretion at 7 AM (10 hours after administration) was inhibited by 28% and 39% (P less than 0.01) by only the 40 mg doses. The response to the 12 noon meal was inhibited by the 9 AM doses of 10, 20, and 40 mg by 45%, 75%, and 85%, respectively (P less than 0.01). The effect of a 40 mg dose given at 9 PM only had dissipated by breakfast (7 AM). The response to the 5 PM meal was suppressed by the 20 and 40 mg doses given at 9 AM by 22% and 35%, respectively (P less than 0.05). Suppression was present in only eight of the subjects after the 20 mg dose but in all 10 after the 40 mg dose. The effect on basal gastric aspirate pH values paralleled those seen on acid output. An association was found between mean plasma concentrations of famotidine and mean inhibition of meal-stimulated acid secretion. However, individual values may not be predictive.

摘要

相似文献

1
The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.
Clin Pharmacol Ther. 1987 Aug;42(2):225-31. doi: 10.1038/clpt.1987.136.
2
Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion.
Am J Med. 1986 Oct 24;81(4B):60-4. doi: 10.1016/0002-9343(86)90601-7.
3
[Inhibition of 24-hour acidity by nizatidine].[尼扎替丁对24小时酸度的抑制作用]
Fortschr Med. 1989 May 10;107(14):321-4.
4
Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?抗胆碱能药物与组胺H2受体拮抗剂对活动性十二指肠溃疡患者夜间胃内酸度有相互作用吗?
Am J Gastroenterol. 1988 Dec;83(12):1371-5.
5
Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.低剂量法莫替丁、雷尼替丁或安慰剂对人五肽胃泌素刺激胃酸分泌的早期和晚期影响。
Aliment Pharmacol Ther. 1996 Oct;10(5):743-7. doi: 10.1046/j.1365-2036.1996.51193000.x.
6
Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.十二指肠溃疡患者睡前服用标准大剂量及半量单次剂量H2拮抗剂实现夜间同等胃酸缺乏:一项临床药理学研究
Am J Gastroenterol. 1988 Sep;83(9):917-22.
7
Clinical pharmacology of famotidine.
Digestion. 1985;32 Suppl 1:15-23. doi: 10.1159/000199257.
8
Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring.法莫替丁睡前单次给药:通过24小时胃内pH监测评估其抗分泌作用。
J Clin Pharmacol. 1987 Oct;27(10):790-3. doi: 10.1002/j.1552-4604.1987.tb02998.x.
9
Clinical pharmacology of famotidine: a summary.法莫替丁的临床药理学:概述。
J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003.
10
The 24-hour acid suppression profile of nizatidine.尼扎替丁的24小时胃酸抑制情况。
Scand J Gastroenterol Suppl. 1987;136:56-60. doi: 10.3109/00365528709094487.

引用本文的文献

1
Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.新型H2受体拮抗剂。临床药代动力学及药物相互作用潜力。
Clin Pharmacokinet. 1988 Oct;15(4):205-15. doi: 10.2165/00003088-198815040-00001.
2
Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.法莫替丁。对其药效学和药代动力学特性以及在消化性溃疡疾病和其他相关疾病中的治疗用途的最新综述。
Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005.
3
Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.
Clin Pharmacokinet. 1990 Jan;18(1):77-81. doi: 10.2165/00003088-199018010-00005.
4
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).用于治疗胃肠道疾病的药物的临床药代动力学(第二部分)。
Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002.
5
Clinical pharmacokinetics of famotidine.法莫替丁的临床药代动力学。
Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003.
6
Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.组胺H2受体拮抗剂的药代动力学和药效学特性。内在活性与有效血药浓度之间的关系。
Clin Pharmacokinet. 1991 Mar;20(3):218-36. doi: 10.2165/00003088-199120030-00004.